07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

DiaPep277: Phase III data

Horizon Pharma plc (NASDAQ:HZNP, Dublin, Ireland) said that Clal Biotechnology Industries Ltd. (Tel Aviv:CBI, Tel Aviv, Israel) provided the Tel Aviv Stock Exchange notice of data from the double-blind, international Phase III DIA-AID 2 trial...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

Hyperion Therapeutics Inc, Clal, Weizmann Institute of Science deal

Hyperion and Clal settled an ongoing dispute related to the development of DiaPep277 and partnered to complete the Phase III DIA-AID 2 trial of the compound to treat Type I diabetes. Hyperion is responsible for...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

DiaPep277: Development discontinued

Hyperion is discontinuing DiaPep277 after discovering research misconduct in development of the Type I diabetes product by employees of Hyperion's Andromeda Biotech Ltd. subsidiary. Hyperion said it uncovered evidence that some Andromeda employees colluded with...
07:00 , Sep 15, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Actavis plc (NYSE:ACT) gained $3.09 to $234.38 last week after FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-4 against approval of an NDA for a fixed-dose combination of nebivolol and valsartan to treat hypertension....
02:52 , Sep 10, 2014 |  BC Extra  |  Company News

Clal, Evotec fall on DiaPep277 revelations

Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) plummeted NIS366.80 (46%) to NIS440 on Tuesday, a day after Hyperion Therapeutics Inc. (NASDAQ:HPTX) said it is terminating diabetes candidate DiaPep277 following alleged research misconduct. Hyperion gained the product...
02:14 , Sep 9, 2014 |  BC Extra  |  Company News

Scandal craters Hyperion's DiaPep277

Hyperion Therapeutics Inc. (NASDAQ:HPTX) said it is terminating diabetes candidate DiaPep277 following research misconduct -- a move that comes just three months after Hyperion spent about $20.4 million to acquire Andromeda Biotech Ltd. and the...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Clal, Hyperion deal

Hyperion completed its acquisition of Clal's Andromeda Biotech Ltd. subsidiary for about $20.5 million in cash and stock up front. Clal received $12.5 million in cash and 312,869 Hyperion shares valued at $8 million based...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Company News

Clal, Hyperion deal

Hyperion will acquire Clal's Andromeda Biotech Ltd. subsidiary in a cash and stock deal. Clal will receive $12.5 million in cash and 312,869 Hyperion shares up front. The shares are valued at $8 million based...
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) gained $2.23 to $35.62 last week after partner AbbVie Inc. (NYSE:ABBV) submitted an NDA to FDA for its all-oral regimen comprising ABT-450 plus AbbVie's Norvir ritonavir, ABT-267 and ABT-333...